Gritstone bio to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will participate in the following investor conferences.
B. Riley Securities' 3rd Annual Oncology Conference (Fireside Chat)
Date and Time: Thursday, January 19, 2023 at 12:30pm ET
Presenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer
2023 BIO CEO & Investor Conference (Panel)
Panel Title: Prioritizing CRO Spending Through a High-Inflation, Sparse-Funding Period
Date and Time: Monday, February 6, 2023 at 2:00pm ET
Presenter: Celia Economides, Chief Financial Officer
SVB Securities Global Biopharma Conference (Fireside Chat)
Date and Time: Thursday, February 16, 2023 at 1:40pm ET
Presenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer
Live webcast and/or archived replays will be available via https://ir.gritstonebio.com/investors/events. Archived replays will be accessible for at least 30 days following the corresponding event.
About Gritstone bio
Gritstone is working to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
